Line 254: | Line 254: | ||
padding-left:3%; | padding-left:3%; | ||
background-size:2.5%; | background-size:2.5%; | ||
+ | } | ||
+ | .end2 { | ||
+ | background-color:#0D014D; | ||
+ | position: absolute; | ||
+ | width: 100%; | ||
+ | height: 200%; | ||
+ | font-family: Corbel; | ||
+ | z-index:+1; | ||
+ | } | ||
+ | .sitemap { | ||
+ | background-color:#0D014D; | ||
+ | position: absolute; | ||
+ | width: 20%; | ||
+ | height: 40%; | ||
+ | font-family: Corbel; | ||
+ | } | ||
+ | .list1 li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/5/58/CGU_Taiwan--sitemap.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:10px; | ||
+ | background-size:9%; | ||
+ | margin-bottom:-20%; | ||
+ | } | ||
+ | .list2 li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:6px; | ||
+ | background-size:7%; | ||
+ | margin-bottom:-10%; | ||
+ | } | ||
+ | .list3 li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:5%; | ||
+ | background-size:2%; | ||
+ | margin-bottom:-10%; | ||
} | } | ||
</style> | </style> | ||
Line 306: | Line 345: | ||
<body> | <body> | ||
+ | <a name='anchor1'></a> | ||
<div class="top"> | <div class="top"> | ||
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg"> | <img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg"> | ||
Line 327: | Line 367: | ||
<div class="left" style="height:40%; border-color:#140731; border-radius:8px;border-width:2px;border-style:solid;"> | <div class="left" style="height:40%; border-color:#140731; border-radius:8px;border-width:2px;border-style:solid;"> | ||
− | <a href="# | + | <a href="#anchor1"><section class="left-tab" style="position:fixed;top:240px;left:35px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()">TOP</section> |
− | <a href=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><section class="left-tab" style="position:fixed;top:275px;left:50px;">Overview</section> |
<a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="position:fixed;top:310px;left:50px;">Design</section> | <a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="position:fixed;top:310px;left:50px;">Design</section> | ||
<a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="position:fixed;top:345px;left:50px;">Background</section> | <a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="position:fixed;top:345px;left:50px;">Background</section> | ||
Line 393: | Line 433: | ||
</div> | </div> | ||
<br><br> | <br><br> | ||
+ | </div> | ||
+ | |||
+ | <div class="end2" style="margin-top:200%;"> | ||
+ | <br> | ||
+ | <ul class="list3" class="margin-left:1%;margin-top:2%;"> | ||
+ | <li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li> | ||
+ | </ul> | ||
+ | <br> | ||
+ | <div class="sitemap" style="margin-left:5%;"> | ||
+ | <br> | ||
+ | <b style="color:white;font-size:40px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br> | ||
+ | <br><br> | ||
+ | <img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | ||
+ | </div> | ||
+ | <br> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:25%;margin-top:-1%;"> | ||
+ | <ul class="list1" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | ||
+ | <ul class="list1" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li> | ||
+ | <br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li> | ||
+ | <br><br> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | ||
+ | <ul class="list1" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li> | ||
+ | <br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | ||
+ | <ul class="list1" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li> | ||
+ | <br> | ||
+ | <ul class="list2" class="margin-left:6%;"> | ||
+ | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | <ul class="list1" class="margin-left:1%;margin-top:-10%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li> | ||
+ | <br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:-5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
</div> | </div> | ||
</body> | </body> | ||
</html> | </html> |
Revision as of 19:12, 26 November 2016
![](https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg)
![](https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg)
Proof of Concept
1. We established stable Leishmania transfectants and
proved the function of promotor with hygromycin drug selection gene
The promoter and the ribosomal binding site of Leishmania genome has not
been elucidated yet. We selected the 5'- untranslated region of a highly expressed
gene, P36, to be the promoter, RBS binding site and other extra function needed for
Leishmania protein expression. We also added a hygromycin resist gene to serve as a
dual functional biobrick of regulatory and selection marker. We provide the user with
the regulation of protein expression and also the drug selection system that is most
commonly and effectively used in Leishmania experiments.
The pSB1C3-5'HYG-OVA-3'UTR was transfected into Leishmania 12-DT strain,
and the transfectants were selected by hygromycin. We obtained the
hygromycin-resistant Leishmania transfectants (Figure 1. B, C). In the negative control
group (Figure 1. A), we could see that almost all cells were dead and the shape of
Leishmania was not normal. It showed that Leishmania transfectants were resistant
to high concentration of hygromycin. The function of 5’HYG was assayed more
precisely in figure 2.
![](https://static.igem.org/mediawiki/2016/3/37/Proof1.jpeg)
![](https://static.igem.org/mediawiki/2016/3/37/Proof1.jpeg)
2. Successfully expressed Hemagglutinin of H1N1
Since we are performing immunology experiments, it is very important that the
antigen is correctly expressed. We used BL21 competent cell to express the HA
sequence and detect the protein by Western blot analysis.
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully recognize the HA protein from Western blot analysis (approximately 62.3kd) when induced by IPTG (Figure 3.).
![](https://static.igem.org/mediawiki/2016/4/4e/Proof2.jpeg)
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully recognize the HA protein from Western blot analysis (approximately 62.3kd) when induced by IPTG (Figure 3.).
![](https://static.igem.org/mediawiki/2016/4/4e/Proof2.jpeg)
3. The antibody production of Leijuvant in mice
The IgG1 antibody titer increased drastically after the second boost on the 15th day.
And the antibody titer reached to peak on the 25th day (Figure 4A.). Inactivated
Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing
inactivated Leishmania, the antibody titer can reach about 80% on the 25th day. The
IgG2a antibody titer of inactivated Leishmania increased extremely on the 20th day
and is significantly higher compare to Alum on the 25th day(Figure 4A.). Leijuvant is a
potential bi-pathway adjuvant that can stimulate both Th1 and Th2 immune
responses.
![](https://static.igem.org/mediawiki/2016/1/19/Proof3.jpeg)
![](https://static.igem.org/mediawiki/2016/1/19/Proof3.jpeg)